Anti-Human CTLA-4 (Tremelimumab Biosimilar)
Catalog #500064
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500064 | 1 mg | $200.00 | ||
| 500064 | 5 mg | $600.00 | ||
| 500064 | 20 mg | $1,250.00 |
Product Details
Tremelimumab biosimilar is a monoclonal antibody targeting CTLA-4 (CD152), which is involved in immune regulation. It is being researched for its potential in treating various cancers, including mesothelioma and liver neoplasms. The biosimilar is commonly produced using mammalian cell expression systems and is available in research-grade formulations.
Specifications
| Clone | Tremelimumab |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG2 |
| Recommended Isotype Control | Human IgG2 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 7.4 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Immunogen | Human CTLA-4 |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |